Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials GroupScott A. Laurie, Lesley Seymour, Eric X. Chen et al.|Journal of Clinical Oncology|2008Cited by 120
719 POSTER Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients (pts) with advanced colorectal cancer (CRC)E. Chen, Lawrence Seymour, Derek J. Jonker et al.|European Journal of Cancer Supplements|2007Cited by 1